(Q34804727)

4 August 2017

1 reference

title

Task force #2--the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference (English)

1 reference

4 August 2017

1

Harlan M Krumholz

1 reference

4 August 2017

Paul A Heidenreich

4

0 references

Daniel B. Mark

object named as

Daniel B Mark

series ordinal

5

0 references

A. David Paltiel

series ordinal

6

object named as

A David Paltiel

1 reference

4 August 2017

2

William S Weintraub

1 reference

4 August 2017

W David Bradford

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Journal of the American College of Cardiology

4 August 2017

published in

1 reference

4 August 2017

volume

40

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

603-615

1 reference

Health spending projections for 2001-2011: the latest outlook

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of a smoking cessation program after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-benefit analysis of walking to prevent coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cardiac rehabilitation and secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cardiac rehabilitation--a cost analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of cardiac rehabilitation after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The practice of discounting in economic evaluations of healthcare interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Oregon's Medicaid ranking and cost-effectiveness: is there any relationship?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The Oregon priority-setting exercise: cost-effectiveness and the rule of rescue, revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

1 reference

7 January 2021

The attribution of attitudes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Five minutes with the Governor.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The costs of prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The cost-effectiveness of counseling smokers to quit.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of a hospital-based smoking cessation intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Variability in the management of hypertension and cost-effectiveness: methodology, community care results and potential cost reductions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Screening for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The Cost Effectiveness of Hypertension Treatment in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

A cost-effectiveness analysis of exercise as a health promotion activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

Physical activity for the over-65s: could it be a cost-effective exercise for the NHS?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902083-1

7 January 2021

10.1016/S0735-1097(02)02083-1

Identifiers

DOI

1 reference

release_ydfvenx3mnd5baoimswu6e6yo4

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ydfvenx3mnd5baoimswu6e6yo4

24 November 2022

mapped directly with Wikidata item

1 reference